The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S6-S12 , October 2007

Postmarketing Clinical Experience in Patients with Skin and Skin-Structure Infections Treated with Daptomycin

This study was presented in part at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2005; Washington, District of Columbia.

  • Robert C. Owens Jr., PharmD

      Affiliations

    • Maine Medical Center, Portland, Maine, USA
    • Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Kenneth C. Lamp, PharmD, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421.
    • ,
  • Lawrence V. Friedrich, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA
    • ,
  • Rene Russo, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA

References 

  1. Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406
  2. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44(suppl A):19–23
  3. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis. 2001;33(suppl 2):S84–S93
  4. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect. 2005;6:283–295(Larchmt)
  5. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML SENTRY Study Group (North America). Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. (United States and Canada, 1997) Diagn Microbiol Infect Dis. 1999;34:65–72
  6. Chambers HF. Community-associated MRSA—resistance and virulence converge. N Engl J Med. 2005;352:1485–1487
  7. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus—an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis. 2003;16:103–124
  8. Tenover FC, Pearson ML. Methicillin-resistant Staphylococcus aureus. Emerg Infect Dis. 2004;10:2052–2053
  9. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  10. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7:327–332
  11. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis. 2005;18:300–305
  12. Centers for Disease Control and Prevention. Laboratory detection of vancomycin-intermediate/resistant Stapylococcus aureus (VISA/VRSA). (April 28, 2006). Retrieved October 1, 2006. from http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_labFAQ.html
  13. Burleson BS, Ritchie DJ, Micek ST, Dunne WM. Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy. 2004;24:1225–1231
  14. Liao CH, Tseng SP, Fang CT, Teng LJ, Hsueh PR. First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother. 2005;55:598–599
  15. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol. 2001;39:3586–3590
  16. Potoski BA, Mangino JE, Goff DA. Clinical failures of linezolid and implications for the clinical microbiology laboratory. Emerg Infect Dis. 2002;8:1519–1520
  17. Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis. 2000;38:51–58
  18. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001;45:1919–1922
  19. King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother. 2001;48:219–223
  20. Critchley IA, Blosser-Middleton RS, Jones ME, Thomsberry C, Sahn DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother. 2003;47:1689–1693
  21. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother. 2003;51:639–649
  22. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45:1799–1802
  23. Cubicin (daptomycin for injection). [prescribing information] Lexington, MA: Cubist Pharmaceuticals, Inc; 2006;
  24. Lewis JS, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–1665
  25. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI Daptomycin 98–01 and 99–01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  26. Rolston KVI, Segreti JA, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120(suppl 10A):S4–S5
  27. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006;26:347–352
  28. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445–1453
  29. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13:1159–1169
  30. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240–245

 Please see the Author Disclosure section at the end of this article.

PII: S0002-9343(07)00659-6

doi: 10.1016/j.amjmed.2007.07.009

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S6-S12 , October 2007

Article Tools